Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma. A Multicenter Phase II Trial

Trial Profile

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma. A Multicenter Phase II Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Nelfinavir (Primary) ; Bortezomib; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Primary endpoint (Response rate based on best response observed during the trial) has been met, according to the abstract presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top